Database for Interstitial Lung Disease

Overview

The purpose of this study is to establish a clinical database for patients bearing at risk for ILD (Interstitial Lung Disease) and to set up a prospective ILD Screening program for these patients.

Full Title of Study: “Clinical Database for the Early Recognition of Pulmonary Parenchymal Involvement in Patients With Systemic Diseases Bearing a Risk for Interstitial Lung Disease”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 31, 2026

Interventions

  • Diagnostic Test: chest CT
    • assessment of interstitial lung disease using chest CT

Arms, Groups and Cohorts

  • prospective patient cohort
    • patients who will undergo the prospective ILD Screening algorithm
  • retrospective patient cohort
    • patients with diagnosed ILD

Clinical Trial Outcome Measures

Primary Measures

  • DLCO%pred (carbon monoxide diffusing capacity) at time of ILD diagnosis
    • Time Frame: 5 years
    • The investigators aim to assess DLCO% pred at time of ILD diagnosis in patients undergoing a ILD Screening algorithm and compare to the retrospective patient cohort with diagnosed ILD and the DLCO%pred at time of ILD diagnosis

Secondary Measures

  • FVC%pred (Forced vital capacity) at time of ILD diagnosis
    • Time Frame: 5 years
    • The investigators aim to assess FVC% pred at time of ILD diagnosis in patients undergoing a ILD Screening algorithm and compare to the retrospective patient cohort with diagnosed ILD and the FVC%pred at time of ILD diagnosis

Participating in This Clinical Trial

Inclusion Criteria

  • Age: ≥ 18 years – patients with a known systemic disease bearing a risk for ILD – signed informed consent (for prospective part) Exclusion Criteria:

  • Age < 18 years – comorbidities severely limiting life-expectancy (e.g. severe cardiovascular conditions, malignant disease)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Medical University of Graz
  • Collaborator
    • Boehringer Ingelheim
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Gabor Kovacs, MD, +43-316-385, gabor.kovacs@klinikum-graz.at

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.